ARROWHEAD PHARMACEUTICALS Reports FY2023 Q3 Earnings Results for June 30 2023
August 22, 2023
🌥️Earnings Overview
On August 7 2023, ARROWHEAD PHARMACEUTICALS ($NASDAQ:ARWR) reported their Fiscal Year 2023 Third Quarter earnings results as of June 30 2023. Revenue for the quarter amounted to USD 15.8 million, a decrease of 51.2% from the same period in the prior year. Additionally, Net Income was recorded at USD -103.0 million, a decrease from the previous year’s -72.0 million.
Market Price
On Monday, ARROWHEAD PHARMACEUTICALS reported their third quarter earnings results for the fiscal year 2023. The company’s stock opened at $31.6 and closed at $30.8, making a 2.7% decrease from its last closing price of $31.6. The company attributed this increase to increased research and development costs related to its pipeline of potential drugs and treatments.
Additionally, the company announced that it was expanding its clinical trials for several of its products and therapies. Overall, ARROWHEAD PHARMACEUTICALS reported mixed results for its third quarter earnings. Despite the decrease in net income and gross margin, the increase in revenues indicates that the company is on track to achieve its growth goals for the upcoming year. The increase in operating expenses shows that the company is investing heavily in research and development, which could potentially lead to substantial rewards in the future. Investors should continue to monitor the company’s progress and take into account any unexpected developments before making any investment decisions. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Arrowhead Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 256.21 | -181.11 | -70.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Arrowhead Pharmaceuticals. More…
| Operations | Investing | Financing |
| -197.37 | -90.22 | 253.76 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Arrowhead Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 795.86 | 413.87 | 3.41 |
Key Ratios Snapshot
Some of the financial key ratios for Arrowhead Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 27.5% | – | -67.3% |
| FCF Margin | ROE | ROA |
| -133.8% | -26.6% | -13.5% |
Analysis
GoodWhale can provide you with a comprehensive analysis of ARROWHEAD PHARMACEUTICALS. Based on our Risk Rating, ARROWHEAD PHARMACEUTICALS is a medium risk investment in terms of financial and business aspects. Furthermore, GoodWhale has detected 2 risk warnings in the income sheet and cashflow statement. If you would like to find out more about these warnings, please register with us. We are here to guide you along the way and provide any assistance required. More…
Peers
It also has a large marketing and sales force that helps it to sell its products to customers.
– Lin BioScience Inc ($TPEX:6696)
Sangamo Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel genomic therapies. The Company’s technology platform is based on zinc finger DNA-binding proteins (ZFPs). The Company’s product candidates are designed to target and modulate the activity of specific genes associated with disease. The Company’s lead product candidates include SB-525, which is in Phase III clinical trials for the treatment of hemophilia A, and SB-913, which is in Phase I/II clinical trials for the treatment of Mucopolysaccharidosis Type I (MPS I).
– Acer Therapeutics Inc ($NASDAQ:ACER)
Acer Therapeutics Inc is a pharmaceutical company that focuses on the development and commercialization of therapies for serious rare and life-threatening diseases. The company’s lead product candidate, Etrasimod, is in clinical development for the treatment of ulcerative colitis, Crohn’s disease, and relapsing multiple sclerosis. Acer also has a portfolio of product candidates in various stages of development for the treatment of rare genetic disorders, including Duchenne muscular dystrophy, Friedreich’s ataxia, alpha-1 antitrypsin deficiency, and Gaucher disease.
– Innovation1 Biotech Inc ($OTCPK:IVBT)
Innovation1 Biotech Inc is a company that focuses on developing innovative treatments for diseases. The company has a market cap of 1.6M as of 2022 and a Return on Equity of -5.58%. The company’s market cap is the value of its outstanding shares of stock. The company’s ROE is a measure of how much profit it generates for shareholders.
Summary
ARROWHEAD PHARMACEUTICALS recently reported their FY2023 Q3 earning results for the period ending June 30 2023. However, with ARROWHEAD PHARMACEUTICALS’ strong portfolio of drugs already on the market and development of new therapies, it may be a good opportunity for investors to buy in at a reduced price. Investors may also want to keep an eye out for any upcoming clinical trials or regulatory approvals that could increase the company’s stock price.
Related Posts
Recent Posts
